Peter Carroll

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Role of active surveillance in the management of localized prostate cancer
    Allison S Glass
    Department of Urology, University of California San Francisco, CA 94143 1695, USA
    J Natl Cancer Inst Monogr 2012:202-6. 2012
  2. pmc The example of CaPSURE: lessons learned from a national disease registry
    Sima P Porten
    Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    World J Urol 29:265-71. 2011
  3. pmc Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer
    Phillip L Ross
    Department of Urology, University of California San Francisco, San Francisco, CA, USA
    BMC Cancer 9:69. 2009
  4. pmc Outcomes of active surveillance for men with intermediate-risk prostate cancer
    Matthew R Cooperberg
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
    J Clin Oncol 29:228-34. 2011
  5. doi request reprint A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy
    Jared Whitson
    Department of Urology, University of California San Francisco, San Francisco, CA 94123, USA
    BJU Int 104:336-9. 2009
  6. ncbi request reprint Ethnic and racial differences in prostate stromal estrogen receptor alpha
    Christopher Haqq
    Department of Medicine, Program in Urologic Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Prostate 65:101-9. 2005
  7. ncbi request reprint Update on chemotherapy for advanced bladder cancer
    Jonathan E Rosenberg
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    J Urol 174:14-20. 2005
  8. pmc High-risk prostate cancer in the United States, 1990-2007
    Matthew R Cooperberg
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1711, USA
    World J Urol 26:211-8. 2008
  9. pmc Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy
    Matthew R Cooperberg
    Department of Urology, University of California, San Francisco, 1600 Divisadero St, A 607, San Francisco, CA 94143 1695, USA
    J Clin Oncol 27:4306-13. 2009
  10. ncbi request reprint Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE
    Charles J Ryan
    Department of Medicine, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 110:81-6. 2007

Collaborators

Detail Information

Publications122 found, 100 shown here

  1. pmc Role of active surveillance in the management of localized prostate cancer
    Allison S Glass
    Department of Urology, University of California San Francisco, CA 94143 1695, USA
    J Natl Cancer Inst Monogr 2012:202-6. 2012
    ..Incorporation of novel biomarkers as well as advanced imaging techniques may improve surveillance strategies by better defining eligibility as well as improving prompt detection of disease progression...
  2. pmc The example of CaPSURE: lessons learned from a national disease registry
    Sima P Porten
    Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    World J Urol 29:265-71. 2011
    ....
  3. pmc Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer
    Phillip L Ross
    Department of Urology, University of California San Francisco, San Francisco, CA, USA
    BMC Cancer 9:69. 2009
    ..We examined the association between genetic variation in CPA4 and intermediate-to-high risk prostate cancer...
  4. pmc Outcomes of active surveillance for men with intermediate-risk prostate cancer
    Matthew R Cooperberg
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
    J Clin Oncol 29:228-34. 2011
    ..Current risk stratification schema identify patients with low-risk disease who are presumed to be most suitable for AS. However, some men with higher risk disease also elect AS; outcomes for such men have not been widely reported...
  5. doi request reprint A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy
    Jared Whitson
    Department of Urology, University of California San Francisco, San Francisco, CA 94123, USA
    BJU Int 104:336-9. 2009
    ..Des Plaines, IL, USA) in patients with high-risk superficial bladder tumours maintains its predictive ability in a multivariate model for recurrence and progression, incorporating clinical and pathological predictors of outcome...
  6. ncbi request reprint Ethnic and racial differences in prostate stromal estrogen receptor alpha
    Christopher Haqq
    Department of Medicine, Program in Urologic Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Prostate 65:101-9. 2005
    ..We identified a relationship between a subset of genes and race/ethnicity using gene expression profiling. Estrogen receptor alpha (ERalpha) was selected for confirmation due to its plausible biological role in cancer susceptibility...
  7. ncbi request reprint Update on chemotherapy for advanced bladder cancer
    Jonathan E Rosenberg
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    J Urol 174:14-20. 2005
    ..Recent years have seen several advances in the treatment of locally advanced and metastatic bladder cancer. We summarize the current state of the art for advanced bladder cancer treatment...
  8. pmc High-risk prostate cancer in the United States, 1990-2007
    Matthew R Cooperberg
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1711, USA
    World J Urol 26:211-8. 2008
    ..This study aimed to describe national trends in presentation, management, and outcomes for men with high risk prostate cancer...
  9. pmc Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy
    Matthew R Cooperberg
    Department of Urology, University of California, San Francisco, 1600 Divisadero St, A 607, San Francisco, CA 94143 1695, USA
    J Clin Oncol 27:4306-13. 2009
    ..We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients...
  10. ncbi request reprint Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE
    Charles J Ryan
    Department of Medicine, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 110:81-6. 2007
    ....
  11. ncbi request reprint Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE)
    Maxwell V Meng
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California San Francisco Cancer Center, University of California San Francisco, San Francisco, California 94115 1711, USA
    J Urol 173:1557-61. 2005
    ..However, men with high risk disease remain a challenge with significant potential for primary treatment failure. We characterize patterns of treatment for high risk prostate cancer in a community based cohort...
  12. ncbi request reprint Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURE
    Natalia Sadetsky
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, Comprehensive Cancer Center, University of California, San Francisco, USA
    Manag Care Interface 18:25-30. 2005
    ..The influence of demographic features and insurance coverage on health care utilization by patients with prostate cancer should be further explored...
  13. doi request reprint Active surveillance for the management of prostate cancer in a contemporary cohort
    Marc A Dall'Era
    Department of Urology and the Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1695, USA
    Cancer 112:2664-70. 2008
    ..In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance...
  14. pmc Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy
    Mark G Swanson
    Department of Radiology, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158, USA
    Magn Reson Med 60:33-40. 2008
    ..7 +/- 2.2%, while Cho+mI and Eth increased 18% in 1 hr at 1 degrees C and a 2250 Hz spin rate...
  15. ncbi request reprint Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE
    Christopher J Kane
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco, USA
    J Urol 173:732-6. 2005
    ..We investigated the association of obesity with prostate cancer case demographics and clinical disease features at presentation...
  16. ncbi request reprint Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities
    Viraj A Master
    Department of Urology, University of California UCSF Comprehensive Cancer Center San Francisco, San Francisco, California 94143 1695, USA
    J Urol 172:2197-202. 2004
    ..We determined whether patients with prostate cancer and local failure could be treated with thermal ablation of the prostate using this novel technology...
  17. ncbi request reprint The impact of patient advocacy: the University of California-San Francisco experience
    Peter R Carroll
    Department of Urology, University of California San Francisco, 94143, USA
    J Urol 172:S58-61; discussion S61-2. 2004
    ..A formal advocacy group was established and advocates were integrated into the administration and planning process in specific areas of the clinical and research program...
  18. doi request reprint Racial differences among boys with testicular germ cell tumors in the United States
    Thomas J Walsh
    Department of Urology, University of California San Francisco, San Francisco, California 94143 1695, USA
    J Urol 179:1961-5. 2008
    ..We hypothesize that recent diversification of race data by cancer registries may allow for more accurate racial classification, and that there are racial differences in the incidence of testicular germ cell tumors in prepubertal boys...
  19. doi request reprint Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE
    Badrinath R Konety
    Department of Urology and Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1695, USA
    J Urol 179:1797-803; discussion 1803. 2008
    ..We examined patterns of primary treatment for prostate cancer in men 75 years or older...
  20. ncbi request reprint Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer
    Thomas J Walsh
    Department of Urology, University of California San Francisco, San Francisco, California 94143 1695, USA
    J Urol 178:1440-6; discussion 1446. 2007
    ..We hypothesize that early orchiopexy is protective against subsequent development of testicular germ cell cancer...
  21. ncbi request reprint Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database
    Badrinath R Konety
    Department of Urology, University of California San Francisco and University of California San Francisco Comprehensive Cancer Center, San Francisco, California 94143, USA
    J Urol 177:1423-5; discussion 1425-6. 2007
    ..We determined if prostate volume determined by preoperative transrectal ultrasound could predict recovery of urinary function and continence following radical prostatectomy...
  22. ncbi request reprint Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE
    Sara J Knight
    San Francisco VA Medical Center, Department of Psychiatry, University of California, San Francisco, California 94121, USA
    Cancer 109:1769-76. 2007
    ..Patient education level and quality of life were examined among men diagnosed with prostate cancer and cared for within an equal-access health care system, the Department of Veterans Affairs Veterans Health Administration (VA)...
  23. ncbi request reprint Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database
    N Sadetsky
    Department of Urology, UCSF Comprehensive Cancer Center, University of California San Francisco, CA 94115, USA
    Prostate Cancer Prostatic Dis 11:280-7. 2008
    ..Future explorations of associations between health care delivery system, cancer care and outcomes are needed...
  24. ncbi request reprint Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging
    Fergus V Coakley
    Department of Urology, The University of California at San Francisco, San Francisco, CA, USA
    BJU Int 99:41-5. 2007
    ....
  25. ncbi request reprint Factors affecting outcomes after radical cystectomy in African Americans
    Badrinath R Konety
    Department of Urology, University of California San Francisco, San Francisco, California 94143 1695, USA
    Cancer 109:542-8. 2007
    ..The authors hypothesized that differences in hospital volume where patients undergo radical cystectomy may be responsible for race-based differences in outcomes after the procedure...
  26. ncbi request reprint Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging
    Antonio C Westphalen
    Department of Radiology, University of California San Francisco, 505 Parnassus Ave, Box 0628, M 372, San Francisco, CA 94143 0628, USA
    Radiology 246:177-84. 2008
    ....
  27. ncbi request reprint Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy
    Matthew R Cooperberg
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Cancer 107:2384-91. 2006
    ..This study used a large external dataset to validate CAPRA...
  28. ncbi request reprint Impact of increased number of biopsies on the nature of prostate cancer identified
    Maxwell V Meng
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Urol 176:63-8; discussion 69. 2006
    ..We determined the impact of the greater number of prostate biopsies on the nature of cancer identified...
  29. ncbi request reprint Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy
    Mark G Swanson
    Department of Radiology, University of California San Francisco, 94107, USA
    Magn Reson Med 55:1257-64. 2006
    ..7, P < 0.01; [PAs](mean) = 5.28 +/- 5.44, P < 0.01). Serial spectra acquired over 12 hr indicated that the degradation of Cho-containing metabolites was minimized by acquiring HR-MAS data at 1 degree C compared to 20 degrees C...
  30. ncbi request reprint Cumulative cost pattern comparison of prostate cancer treatments
    Leslie S Wilson
    Department of Medicine, University of California, San Francisco, California 94143, USA
    Cancer 109:518-27. 2007
    ..The authors compared healthcare utilization and cost patterns of prostate cancer treatments over a span of 5.5 years in 4553 newly diagnosed patients stratified by age and risk group...
  31. ncbi request reprint Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE
    David M Latini
    Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
    Cancer 106:789-95. 2006
    ..The present study examines the impact of Latino ethnicity on these parameters in a large, multiinstitutional database of men with prostate cancer...
  32. doi request reprint Effect of BMI on primary treatment of prostate cancer
    Benjamin J Davies
    Department of Urology, Urology Outcomes Research Group, University of California San Francisco Comprehensive Cancer Center, University of California, San Francisco 94143 1695, USA
    Urology 72:406-11. 2008
    ..This study was designed to assess the relationship between body mass index (BMI) and treatment patterns of prostate cancer patients...
  33. ncbi request reprint The independent impact of extended pattern biopsy on prostate cancer stage migration
    Viraj A Master
    Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco, California 94143 1695, USA
    J Urol 174:1789-93; discussion 1793. 2005
    ..It is still unknown whether the number of biopsies is an independent predictor of tumor size. This is important as a number of studies show that tumor volume is an independent predictor of cancer progression...
  34. doi request reprint Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor
    Natalia Sadetsky
    Department of Urology, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    BJU Int 101:691-7. 2008
    ....
  35. ncbi request reprint The relative impact and future burden of prostate cancer in the United States
    June M Chan
    Department of Epidemiology, School of Medicine, University of California San Francisco, 94143 1695, USA
    J Urol 172:S13-6; discussion S17. 2004
    ..In the last 2 decades there has been increasing awareness of and research on prostate cancer. We considered prostate cancer in the context of other major causes of morbidity and mortality...
  36. doi request reprint Active surveillance for early-stage prostate cancer: review of the current literature
    Marc A Dall'Era
    Department of Urology, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1695, USA
    Cancer 112:1650-9. 2008
    ..The best candidates for active surveillance are being defined, as are predictors of active treatment. The psychosocial ramifications of surveillance for prostate cancer can be profound and future needs and unmet goals will be discussed...
  37. pmc Time trends and local variation in primary treatment of localized prostate cancer
    Matthew R Cooperberg
    University of California, San Francisco, Box 1695, 1600 Divisadero St, A 607, San Francisco, CA 94143 1695, USA
    J Clin Oncol 28:1117-23. 2010
    ..A critical need exists for high-quality comparative effectiveness research in localized prostate cancer to help guide treatment decision making...
  38. doi request reprint Patient decision aids for prostate cancer treatment: a systematic review of the literature
    Grace A Lin
    Division of General Internal Medicine, University of California at San Francisco, 400 Parnassus Avenue, 4th Floor, Box 0320, San Francisco, CA 94143 0320, USA
    CA Cancer J Clin 59:379-90. 2009
    ..Further studies are needed to determine how best to implement DAs into practice, and whether they improve the consistency between patient preferences and treatment choice...
  39. ncbi request reprint Imaging clinically localized prostate cancer
    Rajveer S Purohit
    Department of Urology, 400 Parnassus Avenue, A632, University of California San Francisco, San Francisco, CA 94143 0738, USA
    Urol Clin North Am 30:279-93. 2003
    ..Similarly, ProstaScint scans should be ordered selectively, either before or after primary therapy, rather than routinely in all patients...
  40. pmc Urologist density and county-level urologic cancer mortality
    Anobel Y Odisho
    Department of Urology, University of California, San Francisco, San Francisco, CA 94143 1695, USA
    J Clin Oncol 28:2499-504. 2010
    ..The goal of this study was to determine the effect of increasing urologist density on local prostate, bladder, and kidney cancer mortality...
  41. pmc Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy
    Benjamin N Breyer
    Department of Urology, University of California San Francisco, San Francisco, CA, USA
    BJU Int 106:1734-8. 2010
    ....
  42. doi request reprint Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease
    Adam C Reese
    Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
    J Urol 184:114-9. 2010
    ..We hypothesize that in the context of data available from a contemporary biopsy, clinical stage no longer offers meaningful independent prognostic information for clinically localized prostate cancer...
  43. pmc Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer
    Matthew R Cooperberg
    Department of Urology, University of California, San Francisco, CA, USA
    Cancer 116:5226-34. 2010
    ....
  44. ncbi request reprint A review of measurement of patient preferences for treatment outcomes after prostate cancer
    Deborah P Lubeck
    Department of Urology, University of California San Francisco Mt Zion Comprehensive Cancer Center, San Francisco, California, USA
    Urology 60:72-7; discussion 77-8. 2002
    ..Patients with similar diagnoses and overlapping clinical characteristics may have markedly different preferences for treatment outcomes...
  45. ncbi request reprint Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy
    Gary D Grossfeld
    Department of Urology, University of California, San Francisco Mount Zion Comprehensive Cancer Center, University of California, San Francisco 94115 1711, USA
    Urology 60:57-62; discussion 62-3. 2002
    ..Patient age, lymph node status, and margin status appear to be predictors of secondary treatment with ADT or radiation for patients initially treated with radical prostatectomy...
  46. ncbi request reprint Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer
    Maxwell V Meng
    Mt Zion Comprehensive Cancer Center, Department of Urology, University of California San Francisco, San Francisco, California 94143 0738, USA
    Urology 60:7-11; discussion 11-2. 2002
    ..The appropriateness of such therapy requires further study, including its effect, not only on disease endpoints, but also on resource utilization and health-related quality of life...
  47. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  48. pmc Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer
    June M Chan
    Department of Urology, University of California San Francisco, 1450 3rd Street, San Francisco, CA 94158 9001, USA
    Cancer Causes Control 22:141-50. 2011
    ....
  49. doi request reprint Inaccuracies in assignment of clinical stage for localized prostate cancer
    Adam C Reese
    Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 117:283-9. 2011
    ..One explanation for this lack of predictive power may be the inaccurate application of staging criteria...
  50. ncbi request reprint UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer
    Jared M Whitson
    Department of Urology, University of California San Francisco, San Francisco, California, USA
    Int Braz J Urol 35:664-70; discussion 671-2. 2009
    ..In this study, we investigated the ability of UroVysion to assess response to intravesical therapy in patients with high risk superficial bladder tumors...
  51. pmc The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease
    Sima P Porten
    Department of Urology, University of California, San Francisco, USA
    BJU Int 105:472-5. 2010
    ....
  52. pmc Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis
    Matthew R Cooperberg
    Department of Urology, University of California San Francisco, 1600 Divisadero Street A 607, San Francisco, CA 94143 1695, USA
    J Natl Cancer Inst 101:878-87. 2009
    ....
  53. ncbi request reprint Evaluation of the patient with hematuria
    Edward J Yun
    Department of Urology, University of California at San Francisco, 400 Parnassus Avenue, Room A633, San Francisco, CA 94122, USA
    Med Clin North Am 88:329-43. 2004
    ..This identifies those at highest risk for malignancy while minimizing the number of evaluations in patients unlikely harboring significant disease...
  54. ncbi request reprint Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE
    Joycelyn L Speight
    Department of Radiation Oncology, University of California San Francisco Mt Zion Comprehensive Cancer Center, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:1066-75. 2004
    ....
  55. ncbi request reprint Treatment and outcome of invasive bladder cancer in patients after renal transplantation
    Viraj A Master
    Departments of Urology and Surgery, University of California, San Francisco, California 94143, USA
    J Urol 171:1085-8. 2004
    ..Optimal management and clinical outcome of bladder cancer in renal transplant recipients are not well-defined. We analyzed single institution treatment strategies and outcomes of these patients...
  56. pmc Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database
    Natalia Sadetsky
    UCSF, San Francisco, CA, USA
    Qual Life Res 18:1019-27. 2009
    ..In light of the longer survival in patients with prostate cancer and importance of quality of life, we seek to evaluate the association between HRQOL and survival using traditional and novel techniques...
  57. ncbi request reprint Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 172:S3-5. 2004
  58. ncbi request reprint Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 170:S3-5. 2003
  59. ncbi request reprint Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues
    Mark G Swanson
    Department of Radiology, University of California San Francisco, San Francisco, California 94143 1290, USA
    Magn Reson Med 50:944-54. 2003
    ....
  60. ncbi request reprint Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE
    Maxwell V Meng
    Department of Urology, University of California San Francisco Mt Zion Cancer Center, 94143 0738, USA
    J Urol 170:2279-83. 2003
    ..We identified predictors of eventual prostate cancer treatment in a cohort of men initially choosing WW...
  61. doi request reprint The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer
    Michael L Eisenberg
    Department of Urology, University of California San Francisco, Hellen Diller Family Comprehensive Cancer Center, USA
    BJU Int 105:1237-41. 2010
    ....
  62. pmc Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients
    Felix Moltzahn
    The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
    Cancer Res 71:550-60. 2011
    ..These serum signatures include oncogenic and tumor-suppressive miRNAs, suggesting functional roles in prostate cancer progression...
  63. doi request reprint Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE
    David Aaronson
    University of California San Francisco, 94117, USA
    BJU Int 105:951-5. 2010
    ....
  64. ncbi request reprint Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE
    Charles J Ryan
    Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 24:396-402. 2006
    ..This study describes features that characterize patients with M+ compared to those diagnosed with M0 disease...
  65. pmc A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer
    Pamela L Paris
    Department of Urology, Helen Diller Family Comprehensive Cancer, and Helen Diller Family Comprehensive Cancer Biostatistics Core, University of California at San Francisco, California 94143, USA
    Clin Cancer Res 16:195-202. 2010
    ..Nomograms that use clinical and pathologic variables are often used for risk prediction. Favorable outcomes exist even among men classified by nomograms as being at high risk of recurrence...
  66. pmc Multiparametric magnetic resonance imaging in prostate cancer: present and future
    John Kurhanewicz
    Department of Radiology, University of California, San Francisco, California, USA
    Curr Opin Urol 18:71-7. 2008
    ..The purpose of this article is to review the current status of advanced MRI techniques based on anatomic, metabolic and physiologic properties of prostate cancer with a focus on their impact in managing prostate cancer patients...
  67. ncbi request reprint Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities
    Scott E Eggener
    J Urol 178:2260-7. 2007
    ....
  68. doi request reprint What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database
    Daniel A Barocas
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Urol 180:1330-4; discussion 1334-5. 2008
    ..We determined the percentage of men in a large prostate cancer registry who met criteria predictive of latent prostate cancer. We also assessed the percentage of men meeting these criteria who chose surveillance...
  69. ncbi request reprint Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer
    Stacey L Hart
    Department of Psychology, Ryerson University, Toronto, ON, Canada
    Support Care Cancer 16:161-9. 2008
    ..The objective of this study was to examine treatment satisfaction (TS) as a moderator of the relationship between FOR and QOL...
  70. ncbi request reprint Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
    Henry K Tsai
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 99:1516-24. 2007
    ..We investigated whether androgen deprivation therapy (ADT) use is associated with an increased risk of death from cardiovascular causes in patients treated for localized prostate cancer...
  71. ncbi request reprint Prostate cancer in the Baby Boomer generation: results from CaPSURE
    Charles D Scales
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 70:1162-7. 2007
    ..We sought to characterize prostate cancer (CaP) presentation among this group, and determine whether treatment patterns differ between Baby Boomers and the preceding generation...
  72. doi request reprint Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database
    O Kenneth Macdonald
    Huntsman Cancer Hospital, Salt Lake City, UT 84112, USA
    Urol Oncol 26:271-5. 2008
    ..The role of radiotherapy (RT) for rising PSA after radical prostatectomy (RP) is debatable. We analyzed a large database of men to evaluate for predictors of prostate-specific antigen (PSA) failure after salvage RT...
  73. ncbi request reprint Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes
    Piyush K Agarwal
    Department of Urology, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio, USA
    Cancer 112:307-14. 2008
    ..The authors report the likelihood of treatment failure and the outcomes after salvage therapy among men with prostate cancer who initially either received external-beam radiation therapy (EBRT) or underwent radical prostatectomy (RP)...
  74. pmc Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?
    Alvin R Cabrera
    Department of Radiology, University of California, San Francisco, CA 94143 0628, USA
    Radiology 247:444-50. 2008
    ..To retrospectively determine whether inapparent tumor at endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging is a favorable prognostic finding in prostate cancer patients who select active surveillance for management...
  75. doi request reprint A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy
    Toni K Choueiri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 179:906-10; discussion 910. 2008
    ..Imaging studies to document metastatic disease are frequently obtained but are often uninformative. In this study we identified clinical parameters that were predictive of positive imaging studies...
  76. ncbi request reprint Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 21:2163-72. 2003
    ..To determine whether pretreatment risk groups shown to predict time to prostate cancer-specific mortality (PCSM) after treatment at a single institution retained that ability in a multi-institutional setting...
  77. ncbi request reprint Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE
    Sean P Elliott
    Department of Urologic Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Urol 178:529-34; discussion 534. 2007
    ..We determined the incidence of treatment for urethral stricture, including bladder neck contracture, after primary treatment for clinically localized prostate cancer...
  78. ncbi request reprint Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base
    Kevin A David
    Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
    J Urol 178:451-4. 2007
    ..We reviewed chemotherapy use in patients with stage III transitional cell carcinoma of the bladder from 1998 to 2003 to evaluate perioperative chemotherapy treatment patterns...
  79. ncbi request reprint Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression
    Gary D Grossfeld
    Department ofUrology, University of California, San Francisco, School of Medicine, San Francisco, California 94115 1711, USA
    Urology 59:97-102. 2002
    ....
  80. ncbi request reprint Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 95:1376-83. 2003
    ..Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer-specific mortality by analyzing two multi-institutional databases...
  81. ncbi request reprint Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE
    Susan R Harlan
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Mt Zion Comprehensive Cancer Center, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
    J Urol 170:1804-7. 2003
    ..Watchful waiting (WW) is one option for men with clinically localized prostate cancer. We examined temporal trends in the use of WW, as well as sociodemographic and clinical profiles of men who choose this form of management...
  82. ncbi request reprint Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE)
    Matthew R Cooperberg
    Department of Urology, UCSF Mt Zion Comprehensive Cancer Center, University of California, San Francisco 94115 1711, USA
    J Urol 170:S21-5; discussion S26-7. 2003
    ..We designed a study to characterize time trends in these parameters and their impact on patient risk stratification...
  83. ncbi request reprint Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE
    Christopher J Kane
    Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group, and UCSF Mount Zion Comprehensive Cancer Center, University of California, San Francisco, School of Medicine, 94143 1695, USA
    Urology 62:1035-9. 2003
    ..A patient's educational level may impact a patient's understanding and perception of the risks and benefits of the treatment options for prostate cancer...
  84. ncbi request reprint Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE
    Shilpa S Mehta
    TAP Pharmaceutical Products, Inc, Lake Forest, Illinois, USA
    J Urol 171:215-9. 2004
    ..The pattern and type of treatment offered to such patients have been poorly documented. We determined second treatment patterns in patients with biochemical failure following radical prostatectomy (RP)...
  85. ncbi request reprint Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 96:509-15. 2004
    ....
  86. ncbi request reprint Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure)
    Kirsten L Greene
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California San Francisco 94115 1711, USA
    J Urol 171:2255-9. 2004
    ..We assessed the performance of the Kattan nomogram using the Cancer of the Prostate Strategic Urological Research Endeavor database, a national, largely community based observational disease registry...
  87. ncbi request reprint Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors
    Pamela L Paris
    Comprehensive Cancer Center, University of California at San Francisco, 94115, USA
    Hum Mol Genet 13:1303-13. 2004
    ..Moreover, comparison with an independent set of metastases revealed approximately 40 candidate markers associated with metastatic potential. Copy number aberrations at these loci may define metastatic genotypes...
  88. pmc The changing face of low-risk prostate cancer: trends in clinical presentation and primary management
    Matthew R Cooperberg
    University of California San Francisco Mt Zion Cancer Center, 1600 Divisadero St, 3rd Floor, San Francisco, CA 94115 1711, USA
    J Clin Oncol 22:2141-9. 2004
    ..We sought to characterize temporal trends in clinical presentation and primary disease management among patients with low-risk prostate cancer...
  89. ncbi request reprint Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE
    Matthew R Cooperberg
    Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
    J Urol 170:905-8. 2003
    ..Veterans Affairs (VA) health care system investigators perform large clinical trials in prostate cancer treatment but potential differences between VA and other patient cohorts have not been explored systematically...
  90. pmc National practice patterns and time trends in androgen ablation for localized prostate cancer
    Matthew R Cooperberg
    Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California, San Francisco UCSF Mt Zion Comprehensive Cancer Center, UCSF, San Francisco 941150 1711, USA
    J Natl Cancer Inst 95:981-9. 2003
    ..We describe national trends in the use of androgen deprivation therapy for localized disease...
  91. ncbi request reprint Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE
    Gary D Grossfeld
    Department of Urology, University of California, San Francisco, School of Medicine, San Francisco, California 94143 1711, USA
    Urology 59:560-5. 2002
    ..Previous studies have demonstrated the importance of systematic prostate biopsy results in the risk assessment for newly diagnosed patients with prostate cancer...
  92. ncbi request reprint Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer
    Sean P Elliott
    Department of Urology and the UCSF Mt Zion Comprehensive Cancer Center, University of California, San Francisco, California, USA
    J Urol 168:105-9. 2002
    ..We examined the ability of sextant prostate biopsies in combination with other preoperative data to predict side and sextant site of prostate cancer extracapsular extension in a large cohort of patients...
  93. ncbi request reprint Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor
    Mark S Litwin
    Department of Health Services, University of California, Los Angeles, California 90095, USA
    Cancer 95:54-60. 2002
    ....
  94. ncbi request reprint Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor
    Gary D Grossfeld
    Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and University of California San Francisco Mount Zion Cancer Center, University of California San Francisco, San Francisco, California, USA
    J Urol 168:530-5. 2002
    ..We determined predictors of secondary cancer treatment in patients initially treated with radical prostatectomy or external beam radiation...
  95. ncbi request reprint Neoadjuvant strategies for prostate cancer prior to radical prostatectomy
    Maxwell V Meng
    Department of Urology and the Comprehensive Cancer Center, University of California San Francisco, CA 94115 3006, USA
    Semin Urol Oncol 20:10-8. 2002
    ..Novel neoadjuvant hormonal and chemotherapeutic regimens are under investigation and may improve outcomes for patients undergoing radical prostatectomy...
  96. ncbi request reprint Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109
    Isaac J Powell
    Wayne State University Medical Center, Detroit, Michigan, USA
    J Urol 168:2016-9. 2002
    ....
  97. ncbi request reprint Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups
    Dana Katz
    Urology Outcomes Research Group, Department of Urology and Mt Zion Comprehensive Cancer Center, University of California, San Francisco, USA
    J Urol 168:2092-6. 2002
    ..Support groups may help meet the needs of patients with cancer by providing treatment information and emotional support. We describe men in prostate cancer support groups and compare them to a national registry...
  98. ncbi request reprint Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?
    Gary D Grossfeld
    Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group, University of California San Francisco, USA
    J Urol 168:2510-5. 2002
    ..Prostate cancer incidence and mortality are higher in black than in white American men. We determined whether ethnicity is an independent predictor of disease recurrence in men undergoing radical prostatectomy...
  99. ncbi request reprint Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer
    Gary D Grossfeld
    Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    J Urol 169:157-63. 2003
    ..ml. or a biopsy Gleason score of 8 to 10 are at high risk for disease recurrence after radical prostatectomy. We determined the most important pretreatment predictors of disease recurrence in this high risk population...
  100. ncbi request reprint Prostate cancer 2004: insights from national disease registries
    Matthew R Cooperberg
    Department of Urology, Program in Urologic Oncology, University of California San Francisco, California 94115 1711, USA
    Oncology (Williston Park) 18:1239-47; discussion 1248-50, 1256-8. 2004
    ..The availability of these large databases of patients will be a tremendous asset as prostate cancer management continues to evolve in the coming years...
  101. ncbi request reprint Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Urol 172:S42-6; discussion S46-7. 2004
    ..A short posttreatment prostate specific antigen (PSA)-doubling time (DT) following radical prostatectomy or radiation therapy was evaluated as a surrogate end point for prostate cancer specific mortality (PCSM)...

Research Grants7

  1. Active Surveillance for Early Stage Prostate Cancer: Selection, Monitoring
    Peter Carroll; Fiscal Year: 2006
    ..Two breaks on day one, one break on day two and lunch on day one will allow more informal discussion. A poster session will encourage students, trainees, new investigators, and others interested in this field to attend. ..
  2. Molecular Effects of Nutrition Supplements in Prostate
    Peter Carroll; Fiscal Year: 2007
    ..The DNA, serum, tissue samples and dietary data collected in this trial will be available for other planned future collaborative studies. ..
  3. Male Reproductive Health Research Career Development Program
    Peter Carroll; Fiscal Year: 2007
    ..With these elements, we are committed to nurturing a cadre of UCSF MRHR scholars that will discover and expand knowledge, test innovations, and become future leaders in the field of men's reproductive health. ..